| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
McGill University, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2 [V. S.]; Cancer Therapeutics Branch, Center for Cancer Research, National Cancer Institute [S. B., R. W. R., M. H. K., M. V. B., R. L. P., W. D. F., A. T. F., S. E. B.], Clinical Center, Cardiology [E. T.], and Clinical Center, Pharmacy [B. G.], NIH, Bethesda, Maryland 20892; and The Ohio State University, Columbus, Ohio 43210 [J. B., R. B., K. K. C., S. P. B.]
Purpose: The primary objectives of this trial were to define the maximum tolerated dose (MTD) and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given on a day-1 and day-5 schedule every 21 days. A secondary objective of the trial was to seek evidence of antineoplastic activity.
Patients and Methods: Patients with advanced or refractory neoplasms received depsipeptide by a 4-h i.v. infusion on days 1 and 5 of a 21-day cycle. On the basis of preclinical data suggesting that depsipeptide may have significant cardiac toxicity, patients were treated while receiving continuous cardiac monitoring and were followed with serial cardiac enzyme determinations, electrocardiograms (ECGs), and nuclear ventriculograms (MUGA scans). The starting dose of the trial was 1 mg/m2, and dose escalations proceeded through a total of eight dose levels to a maximum of 24.9 mg/m2. Toxicities were graded using the National Cancer Institute common toxicity criteria, and pharmacokinetics were determined using a liquid chromatography/tandem mass spectrometry method.
Results: Patients (37) received a total of 88 cycles of treatment on study (range: one to eight cycles). Dose-limiting toxicity (DLT) was observed, and the MTD exceeded at a dose of 24.9 mg/m2. The DLTs included grade-3 fatigue (3 patients), grade-3 nausea and vomiting (1 patient), grade-4 thrombocytopenia (2 patients), and grade-4 cardiac arrhythmia (1 patient, atrial fibrillation). The MTD was defined at the seventh dose level (17.8 mg/m2). Reversible ST/T changes and mild reversible dysrhythmias were observed on the post-treatment ECG. There were no clinically significant changes in left ventricular ejection fraction. One patient achieved a partial response. The plasma disposition of depsipeptide was well described by a first-order, two-compartment model. The mean volume of distribution, clearance, t1/2
and t1/2ß at a dose of 17.8 mg/m2 was: 8.6 liters/m2, 11.6 liters/h/m2, 0.42 h, and 8.1 h, respectively. The mean maximum plasma concentration at the MTD was 472.6 ng/ml (range: 249–577.8 ng/ml). Biological assays showed that the serum levels achieved could cause the characteristic cell cycle effects of this agent when serum was added to PC3 cells in culture, as well as increased histone acetylation in patient-derived peripheral blood mononuclear cells.
Conclusion: The MTD of depsipeptide given on a day-1 and -5 schedule every 21 days is 17.8 mg/m2. The DLTs are fatigue, nausea, vomiting, and transient thrombocytopenia and neutropenia. Whereas cardiac toxicity was anticipated based on preclinical data, there was no evidence of myocardial damage. However, reversible ECG changes with ST/T wave flattening were regularly observed. Biologically active serum concentrations were achieved, and 1 patient obtained a partial response. The recommended Phase II dose is 17.8 mg/m2 administered on day 1 and 5 of a 21-day cycle.
Commentary
Clin. Cancer Res. 2002 8: 662-664.
This article has been cited by other articles:
|
|
 |
|
  L. Gore, M. L. Rothenberg, C. L. O'Bryant, M. K. Schultz, A. B. Sandler, D. Coffin, C. McCoy, A. Schott, C. Scholz, and S. G. Eckhardt A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas Clin. Cancer Res., July 15, 2008; 14(14): 4517 - 4525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Liu, H. Cheng, W. Kwan, J. M. Lubieniecka, and T. O. Nielsen Histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in clear cell sarcoma models Mol. Cancer Ther., June 1, 2008; 7(6): 1751 - 1761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Sargeant, R. C. Rengel, S. K. Kulp, R. D. Klein, S. K. Clinton, Y.-C. Wang, and C.-S. Chen OSU-HDAC42, a Histone Deacetylase Inhibitor, Blocks Prostate Tumor Progression in the Transgenic Adenocarcinoma of the Mouse Prostate Model Cancer Res., May 15, 2008; 68(10): 3999 - 4009. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Siu, R. Pili, I. Duran, W. A. Messersmith, E. X. Chen, R. Sullivan, M. MacLean, S. King, S. Brown, G. K. Reid, et al. Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors J. Clin. Oncol., April 20, 2008; 26(12): 1940 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Nakamura, I. Matsushita, E. Kosaka, T. Kondo, and T. Kimura Anti-arthritic effects of combined treatment with histone deacetylase inhibitor and low-intensity ultrasound in the presence of microbubbles in human rheumatoid synovial cells Rheumatology, April 1, 2008; 47(4): 418 - 424. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Fenic, H. M. Hossain, V. Sonnack, S. Tchatalbachev, F. Thierer, J. Trapp, K. Failing, K. S. Edler, M. Bergmann, M. Jung, et al. In Vivo Application of Histone Deacetylase Inhibitor Trichostatin-A Impairs Murine Male Meiosis J Androl, March 1, 2008; 29(2): 172 - 185. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. L. Steele, J. A. Plumb, L. Vidal, J. Tjornelund, P. Knoblauch, A. Rasmussen, C. E. Ooi, P. Buhl-Jensen, R. Brown, T.R. J. Evans, et al. A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors Clin. Cancer Res., February 1, 2008; 14(3): 804 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes Clin. Cancer Res., February 1, 2008; 14(3): 826 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al. Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Gillenwater, M. Zhong, and R. Lotan Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells Mol. Cancer Ther., November 1, 2007; 6(11): 2967 - 2975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G Catalano, R. Poli, M. Pugliese, N. Fortunati, and G. Boccuzzi Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines Endocr. Relat. Cancer, September 1, 2007; 14(3): 839 - 845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Strevel, D. J. Ing, and L. L. Siu Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Keshelava, E. Davicioni, Z. Wan, L. Ji, R. Sposto, T. J. Triche, and C. P. Reynolds Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide J Natl Cancer Inst, July 18, 2007; 99(14): 1107 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-Q. Cheng, M. Yang, and A. M. Matter Characterization of a Gene Cluster Responsible for the Biosynthesis of Anticancer Agent FK228 in Chromobacterium violaceum No. 968 Appl. Envir. Microbiol., June 1, 2007; 73(11): 3460 - 3469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Munster, D. Marchion, E. Bicaku, M. Schmitt, J. H. Lee, R. DeConti, G. Simon, M. Fishman, S. Minton, C. Garrett, et al. Phase I Trial of Histone Deacetylase Inhibition by Valproic Acid Followed by the Topoisomerase II Inhibitor Epirubicin in Advanced Solid Tumors: A Clinical and Translational Study J. Clin. Oncol., May 20, 2007; 25(15): 1979 - 1985. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Gojo, A. Jiemjit, J. B. Trepel, A. Sparreboom, W. D. Figg, S. Rollins, M. L. Tidwell, J. Greer, E. J. Chung, M.-J. Lee, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood, April 1, 2007; 109(7): 2781 - 2790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Myzak, P. Tong, W.-M. Dashwood, R. H. Dashwood, and E. Ho Sulforaphane Retards the Growth of Human PC-3 Xenografts and Inhibits HDAC Activity in Human Subjects Experimental Biology and Medicine, February 1, 2007; 232(2): 227 - 234. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Goldsmith, A. Aguila, K. Steadman, A. Martinez, S. M. Steinberg, M. C. Alley, W. R. Waud, S. E. Bates, and T. Fojo The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems Mol. Cancer Ther., February 1, 2007; 6(2): 496 - 505. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shah, M. A. Villalona-Calero, G. Marcucci, J. C. Byrd, and M. R. Grever HDAC Inhibitors and Cardiac Safety Clin. Cancer Res., February 1, 2007; 13(3): 1068 - 1068. [Full Text] [PDF]
|
|
|
|
|
|
D. L. Marrocco, W. D. Tilley, T. Bianco-Miotto, A. Evdokiou, H. I. Scher, R. A. Rifkind, P. A. Marks, V. M. Richon, and L. M. Butler Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation Mol. Cancer Ther., January 1, 2007; 6(1): 51 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Rubin, N. G.B. Agrawal, E. J. Friedman, P. Scott, K. E. Mazina, L. Sun, L. Du, J. L. Ricker, S. R. Frankel, K. M. Gottesdiener, et al. A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer Clin. Cancer Res., December 1, 2006; 12(23): 7039 - 7045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-L. Chen, J. Sung, M. Cohen, W. H. Chowdhury, M. D. Sachs, Y. Li, Y. Lakshmanan, B. Y. M. Yung, S. E. Lupold, and R. Rodriguez Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells J. Pharmacol. Exp. Ther., November 1, 2006; 319(2): 533 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, C. E. Denlinger, B. K. Rundall, P. W. Smith, and D. R. Jones Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65 J. Biol. Chem., October 20, 2006; 281(42): 31359 - 31368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Fujii, Y. Isaka, Y. Takabatake, M. Mizui, C. Suzuki, S. Takahara, T. Ito, and E. Imai Targeting of interstitial cells using a simple gene-transfer strategy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2745 - 2753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fouladi, W. L. Furman, T. Chin, B. B. Freeman III, L. Dudkin, C. F. Stewart, M. D. Krailo, R. Speights, A. M. Ingle, P. J. Houghton, et al. Phase I Study of Depsipeptide in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Report J. Clin. Oncol., August 1, 2006; 24(22): 3678 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Lundqvist, S. I. Abrams, D. S. Schrump, G. Alvarez, D. Suffredini, M. Berg, and R. Childs Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res., July 15, 2006; 66(14): 7317 - 7325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Shah, P. Binkley, K. Chan, J. Xiao, D. Arbogast, M. Collamore, Y. Farra, D. Young, and M. Grever Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors. Clin. Cancer Res., July 1, 2006; 12(13): 3997 - 4003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Piekarz, A. R. Frye, J. J. Wright, S. M. Steinberg, D. J. Liewehr, D. R. Rosing, V. Sachdev, T. Fojo, and S. E. Bates Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma. Clin. Cancer Res., June 15, 2006; 12(12): 3762 - 3773. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sankaranarayanapillai, W. P. Tong, D. S. Maxwell, A. Pal, J. Pang, W. G. Bornmann, J. G. Gelovani, and S. M. Ronen Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy Mol. Cancer Ther., May 1, 2006; 5(5): 1325 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Heltweg, T. Gatbonton, A. D. Schuler, J. Posakony, H. Li, S. Goehle, R. Kollipara, R. A. DePinho, Y. Gu, J. A. Simon, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res., April 15, 2006; 66(8): 4368 - 4377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Robey, Z. Zhan, R. L. Piekarz, G. L. Kayastha, T. Fojo, and S. E. Bates Increased MDR1 Expression in Normal and Malignant Peripheral Blood Mononuclear Cells Obtained from Patients Receiving Depsipeptide (FR901228, FK228, NSC630176) Clin. Cancer Res., March 1, 2006; 12(5): 1547 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Keriel, C. Rene, C. Galer, J. Zabner, and E. J. Kremer Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors J. Virol., February 1, 2006; 80(3): 1487 - 1496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Denlinger, B. K. Rundall, and D. R. Jones Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1422 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakamura, T. Kukita, T. Shobuike, K. Nagata, Z. Wu, K. Ogawa, T. Hotokebuchi, O. Kohashi, and A. Kukita Inhibition of Histone Deacetylase Suppresses Osteoclastogenesis and Bone Destruction by Inducing IFN-{beta} Production J. Immunol., November 1, 2005; 175(9): 5809 - 5816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Blagosklonny, S. Trostel, G. Kayastha, Z. N. Demidenko, L. T. Vassilev, L. Y. Romanova, S. Bates, and T. Fojo Depletion of Mutant p53 and Cytotoxicity of Histone Deacetylase Inhibitors Cancer Res., August 15, 2005; 65(16): 7386 - 7392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Bevins and S. G. Zimmer It's About Time: Scheduling Alters Effect of Histone Deacetylase Inhibitors on Camptothecin-Treated Cells Cancer Res., August 1, 2005; 65(15): 6957 - 6966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Xiao, Y. Huang, Z. Dai, W. Sadee, J. Chen, S. Liu, G. Marcucci, J. Byrd, J. M. Covey, J. Wright, et al. Chemoresistance to Depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] Is Mediated by Reversible MDR1 Induction in Human Cancer Cell Lines J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Blood, June 15, 2005; 105(12): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. C. Ryan, D. Headlee, M. Acharya, A. Sparreboom, J. B. Trepel, J. Ye, W. D. Figg, K. Hwang, E. J. Chung, A. Murgo, et al. Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma J. Clin. Oncol., June 10, 2005; 23(17): 3912 - 3922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Mitsiades, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, A. Goudopoulou, V. M. Richon, P. A. Marks, and N. Mitsiades Novel Histone Deacetylase Inhibitors in the Treatment of Thyroid Cancer Clin. Cancer Res., May 15, 2005; 11(10): 3958 - 3965. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xiong, S. C. Dowdy, K. C. Podratz, F. Jin, J. R. Attewell, N. L. Eberhardt, and S.-W. Jiang Histone Deacetylase Inhibitors Decrease DNA Methyltransferase-3B Messenger RNA Stability and Down-regulate De novo DNA Methyltransferase Activity in Human Endometrial Cells Cancer Res., April 1, 2005; 65(7): 2684 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Xiao, A. B. Foraker, P. W. Swaan, S. Liu, Y. Huang, Z. Dai, J. Chen, W. Sadee, J. Byrd, G. Marcucci, et al. Efflux of Depsipeptide FK228 (FR901228, NSC-630176) Is Mediated by P-Glycoprotein and Multidrug Resistance-Associated Protein 1 J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 268 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Fabian and B. F. Kimler Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655. [Full Text] [PDF]
|
|
|
|
 |
|
 A. V. Roschke, S. Lababidi, G. Tonon, K. S. Gehlhaus, K. Bussey, J. N. Weinstein, and I. R. Kirsch Karyotypic "state" as a potential determinant for anticancer drug discovery PNAS, February 22, 2005; 102(8): 2964 - 2969. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Byrd, G. Marcucci, M. R. Parthun, J. J. Xiao, R. B. Klisovic, M. Moran, T. S. Lin, S. Liu, A. R. Sklenar, M. E. Davis, et al. A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia Blood, February 1, 2005; 105(3): 959 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Doi, H. Soda, M. Oka, J. Tsurutani, T. Kitazaki, Y. Nakamura, M. Fukuda, Y. Yamada, S. Kamihira, and S. Kohno The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol. Cancer Ther., November 1, 2004; 3(11): 1397 - 1402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Roychowdhury, R. A. Baiocchi, S. Vourganti, D. Bhatt, B. W. Blaser, A. G. Freud, J. Chou, C.-S. Chen, J. J. Xiao, M. Parthun, et al. Selective Efficacy of Depsipeptide in a Xenograft Model of Epstein-Barr Virus-Positive Lymphoproliferative Disorder J Natl Cancer Inst, October 6, 2004; 96(19): 1447 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Gilbert, S. D. Gore, J. G. Herman, and M. A. Carducci The Clinical Application of Targeting Cancer through Histone Acetylation and Hypomethylation Clin. Cancer Res., July 15, 2004; 10(14): 4589 - 4596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Druesne, A. Pagniez, C. Mayeur, M. Thomas, C. Cherbuy, P.-H. Duee, P. Martel, and C. Chaumontet Diallyl disulfide (DADS) increases histone acetylation and p21waf1/cip1 expression in human colon tumor cell lines Carcinogenesis, July 1, 2004; 25(7): 1227 - 1236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Piekarz, R. W. Robey, Z. Zhan, G. Kayastha, A. Sayah, A. H. Abdeldaim, S. Torrico, and S. E. Bates T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance Blood, June 15, 2004; 103(12): 4636 - 4643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Furuya, H. Shimura, H. Suzuki, K. Taki, K. Ohta, K. Haraguchi, T. Onaya, T. Endo, and T. Kobayashi Histone Deacetylase Inhibitors Restore Radioiodide Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin Endocrinology, June 1, 2004; 145(6): 2865 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adachi, Y. Zhang, X. Zhao, T. Minami, R. Kawamura, Y. Hinoda, and K. Imai Synergistic Effect of Histone Deacetylase Inhibitors FK228 and m-Carboxycinnamic Acid Bis-Hydroxamide with Proteasome Inhibitors PSI and PS-341 against Gastrointestinal Adenocarcinoma Cells Clin. Cancer Res., June 1, 2004; 10(11): 3853 - 3862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Mori, T. Matsuda, M. Tadano, T. Kinjo, Y. Yamada, K. Tsukasaki, S. Ikeda, Y. Yamasaki, Y. Tanaka, T. Ohta, et al. Apoptosis Induced by the Histone Deacetylase Inhibitor FR901228 in Human T-Cell Leukemia Virus Type 1-Infected T-Cell Lines and Primary Adult T-Cell Leukemia Cells J. Virol., May 1, 2004; 78(9): 4582 - 4590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Denlinger, M. D. Keller, M. W. Mayo, R. M. Broad, and D. R. Jones Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., April 1, 2004; 127(4): 1078 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
